Monoamine oxidase-B inhibition in Alzheimer's disease

P Riederer, W Danielczyk, E Grünblatt - Neurotoxicology, 2004 - Elsevier
Alzheimer's disease (AD) is the most common cause of dementia in late life. There is still no
clear-cut consensus whether this disease involves genetic or environmental factors or both …

Twenty-five years of amantadine therapy in Parkinson's disease.

W Danielczyk - Journal of neural transmission. Supplementum, 1995 - europepmc.org
Until a few years ago, the anti-parkinsonian effect of amantadine hydrochloride (AHCl) and
amantadine sulfate (AS) could not be explained. The beneficial effect of amantadine, which …

Clinicopathological analysis of dementia disorders in the elderly

K Jellinger, W Danielczyk, P Fischer… - Journal of the neurological …, 1990 - Elsevier
The relative incidence of the major types of dementia disorders and the agreement rates
between clinical and pathological diagnosis were analysed in consecutive autopsy series of …

Glutamatergic-dopaminergic balance in the brain. Its importance in motor disorders and schizophrenia

…, J Kornhuber, W Danielczyk - Arzneimittel …, 1992 - epub.uni-regensburg.de
Dopamine appears to be of less importance in the regulation of psychomotor functions than
was previously thought. A central dopaminergic-glutamatergic balance may be important for …

Therapeutic brain concentration of the NMDA receptor antagonist amantadine

…, G Quack, W Danysz, K Jellinger, W Danielczyk… - …, 1995 - Elsevier
Amantadine (1-amino-adamantane) is clinically used for the management of Parkinson's
disease and drug-induced extrapyramidal symptoms. It has previously been shown that …

Localization of MAO-A and MAO-B in human brain: a step in understanding the therapeutic action of L-deprenyl.

…, E Kienzl, G Birkmayer, W Danielczyk… - Advances in …, 1987 - europepmc.org
The discovery that MAO can be differentiated biochemically and pharmacologically into two
forms, types A and B, with different substrate specificities and inhibitor sensitivities has …

Synaptic pathology in Alzheimer's disease: immunological data for markers of synaptic and large dense-core vesicles

…, C Bancher, K Jellinger, E Floor, W Danielczyk… - Neuroscience, 1992 - Elsevier
We have analysed several markers for small synaptic vesicles (synaptin-synaptophysin, p65
and SV2) and large dense-core vesicles (chromogranin A, secretogranin II/chromogranin C) …

Human post-mortem striatal α4β2 nicotinic acetylcholine receptor density in schizophrenia and Parkinson's syndrome

…, W Paulus, G Ransmayr, T Tatschner, W Danielczyk… - Neuroscience …, 2000 - Elsevier
The density of nicotinic α4β2 receptors, which are believed to largely mediate nicotine's
effects, has been reported to be decreased in post-mortem hippocampus of patients with …

Up-regulation of striatal adenosine A2A receptors in schizophrenia

…, W Paulus, G Ransmayr, T Tatschner, W Danielczyk… - …, 2003 - journals.lww.com
Adenosine A 2A receptors have been implicated in the pathophysiology of schizophrenia by
clinical, anatomical, biochemical and genetic studies. We hypothesized that a genetically …

Treatment of impaired cerebral function in psychogeriatric patients with memantine-results of a phase II double-blind study

L Ambrozi, W Danielczyk - Pharmacopsychiatry, 1988 - thieme-connect.com
Memantine was investigated in a phase II double-blind trial on 30 elderly patients by
comparison with a placebo with the aid of several psychometric tests. It was found that …